259 related articles for article (PubMed ID: 19258598)
1. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.
Novak U; Rinaldi A; Kwee I; Nandula SV; Rancoita PM; Compagno M; Cerri M; Rossi D; Murty VV; Zucca E; Gaidano G; Dalla-Favera R; Pasqualucci L; Bhagat G; Bertoni F
Blood; 2009 May; 113(20):4918-21. PubMed ID: 19258598
[TBL] [Abstract][Full Text] [Related]
2. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
[TBL] [Abstract][Full Text] [Related]
3. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma.
Honma K; Tsuzuki S; Nakagawa M; Karnan S; Aizawa Y; Kim WS; Kim YD; Ko YH; Seto M
Genes Chromosomes Cancer; 2008 Jan; 47(1):1-7. PubMed ID: 17886247
[TBL] [Abstract][Full Text] [Related]
4. Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.
Liu F; Karube K; Kato H; Arita K; Yoshida N; Yamamoto K; Tsuzuki S; Kim W; Ko YH; Seto M
Int J Clin Exp Pathol; 2012; 5(5):436-41. PubMed ID: 22808296
[TBL] [Abstract][Full Text] [Related]
5. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
Honma K; Tsuzuki S; Nakagawa M; Tagawa H; Nakamura S; Morishima Y; Seto M
Blood; 2009 Sep; 114(12):2467-75. PubMed ID: 19608751
[TBL] [Abstract][Full Text] [Related]
6. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
Schmitz R; Hansmann ML; Bohle V; Martin-Subero JI; Hartmann S; Mechtersheimer G; Klapper W; Vater I; Giefing M; Gesk S; Stanelle J; Siebert R; Küppers R
J Exp Med; 2009 May; 206(5):981-9. PubMed ID: 19380639
[TBL] [Abstract][Full Text] [Related]
7. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands.
Chanudet E; Ye H; Ferry J; Bacon CM; Adam P; Müller-Hermelink HK; Radford J; Pileri SA; Ichimura K; Collins VP; Hamoudi RA; Nicholson AG; Wotherspoon AC; Isaacson PG; Du MQ
J Pathol; 2009 Feb; 217(3):420-30. PubMed ID: 19006194
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL.
Philipp C; Edelmann J; Bühler A; Winkler D; Stilgenbauer S; Küppers R
Int J Cancer; 2011 Apr; 128(7):1747-50. PubMed ID: 20533286
[TBL] [Abstract][Full Text] [Related]
9. A20 inactivation in ocular adnexal MALT lymphoma.
Bi Y; Zeng N; Chanudet E; Huang Y; Hamoudi RA; Liu H; Dong G; Watkins AJ; Ley SC; Zou L; Chen R; Zhu X; Du MQ
Haematologica; 2012 Jun; 97(6):926-30. PubMed ID: 22207688
[TBL] [Abstract][Full Text] [Related]
10. A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma.
Giulino L; Mathew S; Ballon G; Chadburn A; Barouk S; Antonicelli G; Leoncini L; Liu YF; Gogineni S; Tam W; Cesarman E
Blood; 2011 May; 117(18):4852-4. PubMed ID: 21406721
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.
Rinaldi A; Mian M; Chigrinova E; Arcaini L; Bhagat G; Novak U; Rancoita PM; De Campos CP; Forconi F; Gascoyne RD; Facchetti F; Ponzoni M; Govi S; Ferreri AJ; Mollejo M; Piris MA; Baldini L; Soulier J; Thieblemont C; Canzonieri V; Gattei V; Marasca R; Franceschetti S; Gaidano G; Tucci A; Uccella S; Tibiletti MG; Dirnhofer S; Tripodo C; Doglioni C; Dalla Favera R; Cavalli F; Zucca E; Kwee I; Bertoni F
Blood; 2011 Feb; 117(5):1595-604. PubMed ID: 21115979
[TBL] [Abstract][Full Text] [Related]
12. Frequent inactivation of A20 in B-cell lymphomas.
Kato M; Sanada M; Kato I; Sato Y; Takita J; Takeuchi K; Niwa A; Chen Y; Nakazaki K; Nomoto J; Asakura Y; Muto S; Tamura A; Iio M; Akatsuka Y; Hayashi Y; Mori H; Igarashi T; Kurokawa M; Chiba S; Mori S; Ishikawa Y; Okamoto K; Tobinai K; Nakagama H; Nakahata T; Yoshino T; Kobayashi Y; Ogawa S
Nature; 2009 Jun; 459(7247):712-6. PubMed ID: 19412163
[TBL] [Abstract][Full Text] [Related]
13. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
[TBL] [Abstract][Full Text] [Related]
14. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome.
Nocturne G; Boudaoud S; Miceli-Richard C; Viengchareun S; Lazure T; Nititham J; Taylor KE; Ma A; Busato F; Melki J; Lessard CJ; Sivils KL; Dubost JJ; Hachulla E; Gottenberg JE; Lombès M; Tost J; Criswell LA; Mariette X
Blood; 2013 Dec; 122(25):4068-76. PubMed ID: 24159176
[TBL] [Abstract][Full Text] [Related]
15. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.
Clipson A; Wang M; de Leval L; Ashton-Key M; Wotherspoon A; Vassiliou G; Bolli N; Grove C; Moody S; Escudero-Ibarz L; Gundem G; Brugger K; Xue X; Mi E; Bench A; Scott M; Liu H; Follows G; Robles EF; Martinez-Climent JA; Oscier D; Watkins AJ; Du MQ
Leukemia; 2015 May; 29(5):1177-85. PubMed ID: 25428260
[TBL] [Abstract][Full Text] [Related]
16. High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.
Vela V; Juskevicius D; Gerlach MM; Meyer P; Graber A; Cathomas G; Dirnhofer S; Tzankov A
Hematol Oncol; 2020 Aug; 38(3):284-292. PubMed ID: 32012328
[TBL] [Abstract][Full Text] [Related]
17. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
[TBL] [Abstract][Full Text] [Related]
18. A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology.
Hirsch B; Grünbaum M; Wagner F; Bi Y; Lucka L; Du MQ; Stein H; Dürkop H
Histopathology; 2012 May; 60(6B):E19-27. PubMed ID: 22393903
[TBL] [Abstract][Full Text] [Related]
19. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.
Yan Q; Huang Y; Watkins AJ; Kocialkowski S; Zeng N; Hamoudi RA; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
Haematologica; 2012 Apr; 97(4):595-8. PubMed ID: 22102703
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.
Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA
Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
